医学
加药
中止
内科学
脂肪性肝炎
胃肠病学
不利影响
队列
养生
肝功能
耐受性
纤维化
肝功能检查
血糖性
内分泌学
药代动力学
糖尿病
药理学
前瞻性队列研究
脂肪肝
血脂异常
肝损伤
临床研究阶段
肝酶
血脂谱
药品
二甲双胍
白细胞减少症
作者
Naim Alkhouri,Madhavi Rudraraju,Mark T. Leibowitz,Robert A. Jenders,Anita Kohli,Mazen Noureddin,Rashmee Patil,Iulia Cristina Tudor,Jeffrey D. Botbyl,Jeevan R. Kunta,Amanda Kesner-Hays,Rafael Mayoral Moñibas,Aprille Espinueva,Kavita Juneja,Kris V. Kowdley
出处
期刊:Hepatology
[Lippincott Williams & Wilkins]
日期:2026-10-26
标识
DOI:10.1097/hep.0000000000001886
摘要
BACKGROUND AND AIMS: Miricorilant, an oral nonsteroidal selective glucocorticoid receptor modulator, is being investigated as a therapy that modulates hepatic cortisol activity in patients with metabolic dysfunction-associated steatohepatitis (MASH). This phase 1b study (NCT05117489) evaluated miricorilant's efficacy and safety. APPROACH AND RESULTS: Seventy patients with presumed MASH received oral miricorilant daily (30-150 mg) or intermittent (100-200 mg once, twice, or thrice weekly) dosing regimens for 12 or 24 weeks. Across dosing regimens, reductions in relative liver fat content (LFC) ranged from 10.1% to 76.6%. Improvements in MASH liver function markers and the enhanced liver fibrosis (ELF) score were observed across regimens. Treatment-emergent adverse events (TEAEs) leading to drug interruption/discontinuation occurred in 12.9% of patients (n=9) each; most were due to aminotransferase elevations during an excessively rapid drop in LFC (up to 70.2% at week 6) and in patients receiving daily dosing. Intermittent dosing enabled more patients to complete 12 weeks of treatment without discontinuation due to TEAEs. Intermittent dosing with miricorilant 100 mg twice weekly had the best benefit-risk profile; this cohort demonstrated a mean LFC reduction of 28.2% at week 12, with a corresponding decline in liver enzymes (ALT, -3.8 U/L; AST, -6.0 U/L). Patients in this cohort also had numerical improvement in lipid profiles, glycemic markers, and fibrosis biomarkers. CONCLUSIONS: Intermittent miricorilant dosing of 100 mg twice weekly achieved meaningful reductions in LFC and improved liver health markers with a favorable safety profile. This regimen is being evaluated in the phase 2b MONARCH study (NCT06108219).
科研通智能强力驱动
Strongly Powered by AbleSci AI